Hologic, Inc. (Nasdaq: HOLX) is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems, and surgical products, with an emphasis on serving the healthcare needs of women throughout the world.
At Hologic, we are on a mission: to help women everywhere lead longer, healthier lives. It is our reason for being and the single focus of every breakthrough we pursue, every solution we design, every investment we make.
Hologic is a market leader in mammography and breast biopsy, breast magnetic resonance imaging, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia and uterine fibroids, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging, and molecular diagnostic products including human papillomavirus (HPV) testing and reagents for a variety of DNA and RNA analysis applications.
We are proud of our achievements and conscious of the responsibility that our leadership position brings with it. We believe that the health issues facing women today deserve and demand the singular dedication of a passionate company.
Our core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health.
"You have cancer. Fortunately, we caught it early."
At Hologic, our focus and concentration on breast cancer is unmatched. We know of no other major healthcare company that devotes a higher percentage of its resources to the development and deployment of screening, diagnostic and therapeutic technologies to meet the challenges of this disease.
It's one reason why so many radiologists, surgeons and radiation oncologists rely on Hologic solutions for digital mammography, breast biopsy and accelerated partial breast irradiation.
Hologic is proud to be the first company to receive FDA approval for 3D breast, tomosynthesis. An additional screening tool in the fight against breast cancer, our Selenia® Dimensions® 3D breast tomosynthesis system addresses the primary limitations of 2D mammography, the superimposition of normal breast tissue. Tomosynthesis allows doctors to examine breast tissue one layer at a time.
Our Selenia digital mammography systems and SecurView® diagnostic workstations are leading the industry in the transition from analog to a digital environment. More than a single technology, Selenia digital mammography represents an integrated suite of technical advances, pushing the science of breast cancer detection forward. We understand the constantly changing digital environment and the need for a flexible, compatible computer-aided detection solution. Our
ImageChecker® CAD system delivers proven performance and has been the leading CAD technology for more than a decade. For added comfort, our MammoPad® breast cushion offers a softer, warmer mammogram to help lower the patient's anxiety allowing the technologist to obtain more of the chest wall in the image and ensure even compression of the breast.
If a suspicious lesion is detected, we support the next clinical steps: our ATEC®, Eviva® and Celero® breast biopsy systems, coupled with our MultiCare® Platinum prone biopsy table and StereoLoc® II upright biopsy platform, provide clinicians with easier and more effective access to lesions with fewer needle insertions.
Should cancer be detected in its early stages, many women are candidates for the Hologic MammoSite® radiation therapy system, a unique and welcomed clinical option and a patient-friendly alternative to traditional whole breast radiation. MammoSite is the most widely used and accepted method of accelerated partial breast irradiation in the United States. With its multi-lumen design, our new MammoSite ML device gives radiation oncologists the ability to shape the radiation dose
for typical cases and treat patients who are otherwise not appropriate candidates for traditional brachytherapy.
Our ground breaking Sentinelle™ breast magnetic resonance imaging coils allow healthcare providers to take advantage of unique technologies not available in traditional tabletop systems. Our Sentinelle Breast MRI auxiliary table provides complete and open access for intervention, and award winning design for optimal patient comfort and workflow. And our Aegis™ imaging and interventional computer software aids in the guidance of biopsy procedures and allows the
radiologist to view and manipulate the MRI images in three dimensions.
In many markets, our breast cancer screening solutions and interventional therapies are the preferred choice. As an extension of our global commitment to women's healthcare, we support humanitarian programs with contributions of imaging, screening, diagnostic and therapeutic equipment to a variety of countries, including Macedonia, Tanzania, Nicaragua, Thailand and South Africa. Through these important initiatives, many women are receiving preventive screening exams for the first time in
We believe that women deserve a better answer.
We take great pride in the screening and diagnostic capabilities that we have developed for physicians focused on prenatal and gynecological health.
The most widely known are the ThinPrep® Pap test and ThinPrep Imaging system. For women, they mean confidence: ThinPrep technology has set new standards for cervical cancer screening that both women and the medical community have come to rely on. With the ThinPrep Pap test, there are much higher detection levels for precancerous cells, giving physicians and patients more time to undertake appropriate treatment.
A pregnant woman has special concerns: her baby's health, her own health. Our Rapid fFN® (fetal fibronectin) test gives OBGYNs a clear picture of preterm birth probabilities - valuable information to support treatment options for the mother if necessary. We offer a second important test for women during pregnancy called InPlex® CF: a molecular test that can identify genetic mutations associated with cystic fibrosis in both the mother and the unborn child.
Our Cervista® HPV HR test, designed to detect the 14 high-risk types of human papillomavirus (HPV) known to cause cervical cancer, is the first HPV DNA test approved by the FDA in more than 10 years. Cervista HPV 16/18 is the first HPV test approved for genotyping for HPV types 16 and 18, known to be associated with approximately 70 percent of all cervical cancers in the United States. Both of these HPV tests complement our ThinPrep Pap test platform for early detection of
HPV is the most common sexually transmitted disease in the United States and is recognized as the cause of most cervical cancers. To help prevent the onset of disease, the American College of Obstetrics and Gynecology suggests routine Pap and HPV testing for women over the age of 30 to identify women most likely to develop cervical cancer.
Our Cellient® automated cell block system is the first commercially available fully automated system that allows individual cells or small tissue samples to be processed for histological examination. The vacuum-assisted filtration concentrates available cells within the block. The result is diagnostically useful, high-quality blocks that are created in less than an hour and can be reviewed efficiently.
We continue to support a woman's gynecological health past her child-bearing years. NovaSure® endometrial ablation is a one-time, five-minute procedure that can lighten or end a woman's heavy periods without hormones or hysterectomy. It is the market leading endometrial ablation technology for the condition of menorrhagia. Thanks to the NovaSure system, more than one million women have been able to dramatically improve the quality of their lives, freed from the
debilitating impact of excessive menstrual bleeding.
Our MyoSure® hysteroscopic tissue removal system is a new and innovative treatment that enables incision-less, fast removal of intracavitary fibroids and polyps and provides effective relief of abnormal uterine bleeding symptoms. The MyoSure system is an ideal treatment option for women seeking to preserve uterine form and function.
In the U.S. roughly four out of ten white women over age 50 will experience a hip, spine, or wrist fracture sometime during the remainder of their lives. Looking ahead, the lifetime risk of fractures will increase for all ethnic groups as people live longer. Early detection and treatment can mean a lifetime of health and vitality for women.
Osteoporosis is often a silent thief - when she least expects it; osteoporosis robs a woman of her vitality, her confidence, her spirit. Helping women fight this disease requires especially sensitive care from their physicians - supported by early detection and appropriate treatment to rebuild strong and healthy bones.
Our work in the detection of osteoporosis is one more example of our special commitment to addressing those health challenges that threaten women most severely.
We pioneered dual x-ray bone densitometry technology, which has become the industry standard for assessing bone health. Using our Discovery™ system, clinicians can identify fractures not discernible by normal examinations. An added benefit of these advances is the growing use of the same technologies to measure body composition and support the diagnosis of heart disease. Today there is no definitive cure for osteoporosis. But we will continue to make state-of-the art detection
and diagnosis solutions until medical science can develop an answer.
One area that is receiving a great deal of attention in both Hologic and the medical press is our new technology, breast tomosynthesis. The Hologic Selenia® Dimensions® system is the first commercially available breast cancer screening and diagnostic technology to deliver on the extraordinary promise of breast tomosynthesis - a breakthrough Hologic believes will revolutionize how breast cancer is detected today. The Selenia Dimensions system delivers the exceptional 2D images the
industry has come to expect from Hologic and, for the first time ever, gives radiologists the option of offering their patients a conventional 2D digital mammogram and a 3D tomosynthesis exam - all under one compression, in just seconds. The Selenia Dimensions system is available commercially in the United States and in more than 40 countries including locations in North America, Europe, Latin America, Asia, and Australia.
Each year, we spend millions of dollars on research and development to deliver more advanced and innovative imaging, intervention, and treatment solutions to save even more lives. Our research is focused on pushing the boundaries of science and technology to accelerate the screening and detection of disease, identify less invasive therapies, and uncover technological breakthroughs in diagnostics and therapeutics. The results of our relentless explorations are evident in the products we create,
the screening programs we enable and the improvements in patient outcomes our technologies help make possible.
We know of no other major healthcare company that devotes a higher percentage of its resources to the development and deployment of screening, diagnostic and therapeutic technologies designed to help doctors see better, know sooner and reach further.
This is our commitment to the women of the world.
With centers of operation in North America, Europe, Central America, Australia and Asia, Hologic is focused on extending its medical systems and solutions to benefit women around the world. We have the strength and resources of a billion dollar company and the vision of leaders committed to a broad spectrum of women's health issues. Our 6,000 associates are driven toward breakthrough achievements in research, product development and the worldwide distribution of healthcare solutions.
And we have the unwavering partnerships of thousands of healthcare professionals who match our dedication to extending and enriching the lives of women everywhere. As a result, our screening solutions and interventional therapies are the preferred choice for large numbers of physicians, administrators and technologists throughout the developed world.
Together we cannot fail.